Filter Results:
(1,304)
Show Results For
- All HBS Web
(1,304)
- People (4)
- News (228)
- Research (903)
- Events (4)
- Multimedia (7)
- Faculty Publications (498)
Show Results For
- All HBS Web
(1,304)
- People (4)
- News (228)
- Research (903)
- Events (4)
- Multimedia (7)
- Faculty Publications (498)
- November 2007 (Revised October 2009)
- Case
Ligand Pharmaceuticals Incorporated
In an activist role, the hedge fund Third Point LLC has three board seats and an ownership stake of 9.5% in Ligand Pharmaceuticals, Inc., a specialty pharmaceutical company. Third Point believed that Ligand had a strong drug portfolio and pipeline but that it was... View Details
Keywords: Mergers and Acquisitions; Private Equity; Investment Activism; Investment Funds; Governing and Advisory Boards; Bids and Bidding; Ownership Stake; Pharmaceutical Industry; United States
El-Hage, Nabil N., and Michael Gorzynski. "Ligand Pharmaceuticals Incorporated." Harvard Business School Case 208-019, November 2007. (Revised October 2009.)
- August 1994 (Revised March 1995)
- Supplement
Kurt Landgraf and Du Pont Merck Pharmaceutical Company (B)
Supplements the (A) case. View Details
Gentile, Mary C., and Sarah Gant. "Kurt Landgraf and Du Pont Merck Pharmaceutical Company (B)." Harvard Business School Supplement 395-035, August 1994. (Revised March 1995.)
- 2000
- Book
Merchants to Multinationals
By: Geoffrey Jones
This book examines the evolution of multinational trading companies from the eighteenth century to the present day. During the Industrial Revolution, British merchants established overseas branches which became major trade intermediaries, and later engaged in foreign... View Details
Keywords: Competency and Skills; Trade; Foreign Direct Investment; Multinational Firms and Management; Corporate Governance; Growth and Development; Human Resources; Information Management; Relationships; Corporate Strategy; Africa; Asia; Latin America
Jones, Geoffrey. Merchants to Multinationals. Oxford: Oxford University Press, 2000. (Winner of Newcomen-Harvard Book Award Given once every three years to the best work in the field of business history published in the United States.)
- 2022
- Book
Les multinationales suisses dans l'arène politique (1942–1993) [Swiss Multinationals in the Political Arena (1942–1993)]
By: Sabine Pitteloud
En décembre 2020, les Suisses votaient sur l’initiative populaire « pour des multinationales responsables ». Cet épisode récent a rappelé que la régulation de l’activité des sociétés multinationales fait l’objet de luttes politiques, auxquelles participent les... View Details
Keywords: Multinational Enterprise; Multinational Companies; Multinational Corporations; Lobbying; Business ＆ Government Relations; Labor Relations; Relocation; Offshoring And Outsourcing; Corporate Regulation; Transnational Regulation; Multinational Firms and Management; Business and Government Relations; Governing Rules, Regulations, and Reforms; International Relations; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Switzerland
Pitteloud, Sabine. Les multinationales suisses dans l'arène politique (1942–1993) [Swiss Multinationals in the Political Arena (1942–1993)]. Genève, Suisse: Librairie Droz, 2022, French ed.
- 8 Mar 2012
- Other Presentation
Competing by Saving Lives: How Pharmaceutical and Medical Device Companies Create Shared Value in Global Health
How Pharmaceutical and Medical Device Companies Create Shared Value in Global Health View Details
Porter, Michael E. "Competing by Saving Lives: How Pharmaceutical and Medical Device Companies Create Shared Value in Global Health." Creating Shared Value in Global Health, FSG, New York City, NY, United States , March 8, 2012.
- 2012
- Report
Competing by Saving Lives: How Pharmaceutical and Medical Device Companies Create Shared Value in Global Health
By: Mark R. Kramer, Kyle Peterson, Matthew Rehrig, Mike Stamp and Samuel Kim
Examples of how pharmaceutical and medical companies are addressing unmet health needs in low- and middle- income economies, creating shared value by providing products and services that tackle global health problems. View Details
Keywords: Shared Value; Low- And Middle-income Economies; Health Care and Treatment; Global Range; Pharmaceutical Industry; Pharmaceutical Industry
Kramer, Mark R., Kyle Peterson, Matthew Rehrig, Mike Stamp, and Samuel Kim. "Competing by Saving Lives: How Pharmaceutical and Medical Device Companies Create Shared Value in Global Health." Report, FSG, 2012.
- October 2012
- Teaching Plan
Vertex Pharmaceuticals and the Cystic Fibrosis Foundation: Venture Philanthropy Funding for Biotech (TP)
By: Robert F. Higgins
This is the teaching note related to HBS case 808005. In 2001, Vertex Pharmaceuticals Incorporated acquired the San Diego-based biotech company, Aurora Biosciences. The combination of Vertex's and Aurora's technologies would improve the flow of novel drug candidates... View Details
Keywords: Venture Philanthropy; Biotechnology; Funding Philanthropy Venture; Cystic Fibrosis; Foundations; Pharmaceuticals; Mergers and Acquisitions; For-Profit Firms; Venture Capital; Philanthropy and Charitable Giving; Science-Based Business; Nonprofit Organizations; Pharmaceutical Industry; Pharmaceutical Industry; United States; San Diego
- September 2006 (Revised March 2010)
- Case
Teva Pharmaceutical Industries, Ltd
By: Tarun Khanna, Krishna G. Palepu and Claudine Deborah Madras
How do companies develop a strategy that is both low-cost and differentiated without becoming squeezed in the middle? Describes how Teva, Israel's first and largest multinational, achieved its globally dominant position in generic pharmaceuticals, an industry that has... View Details
Keywords: Multinational Firms and Management; Emerging Markets; Rank and Position; Competitive Strategy; Pharmaceutical Industry; India; Israel
Khanna, Tarun, Krishna G. Palepu, and Claudine Deborah Madras. "Teva Pharmaceutical Industries, Ltd." Harvard Business School Case 707-441, September 2006. (Revised March 2010.)
- September 1999 (Revised September 2005)
- Case
Strategic Deal Making at Millennium Pharmaceuticals
A small start-up in 1993, Millennium Pharmaceuticals was a name-brand biotechnology company by the end of 1998, with a market capitalization of $1.4 billion. The Cambridge-based company's growth strategy had relied heavily on building alliances for early-stage drug... View Details
Keywords: Alliances; Negotiation Deal; Growth and Development Strategy; Pharmaceutical Industry; Cambridge
Watkins, Michael D., and Sarah Matthews. "Strategic Deal Making at Millennium Pharmaceuticals." Harvard Business School Case 800-032, September 1999. (Revised September 2005.)
- January 2003 (Revised June 2005)
- Case
Multinationals as Engines of Growth?
Reviews the issues surrounding estimating the impact over time of multinationals on host economies. Uses a series of short historical case studies, including the role of United Fruit in the "banana" republics of Central America, oil and banking in Iran before the... View Details
Keywords: Business History; Multinational Firms and Management; Trade; Growth and Development; Corporate Entrepreneurship; Globalized Economies and Regions; Iran; United States; Malaysia; Japan
Jones, Geoffrey G. "Multinationals as Engines of Growth?" Harvard Business School Case 803-108, January 2003. (Revised June 2005.)
- February 2016 (Revised February 2017)
- Case
Alvogen
By: Daniel Isenberg and William Kerr
Alvogen is a young Icelandic generic pharmaceutical company, whose CEO believes that his global strategy will give them an edge in this competitive industry.
Robert Wessman, Alvogen’s CEO, was also previously the CEO of Actavis, another Icelandic generics... View Details
Robert Wessman, Alvogen’s CEO, was also previously the CEO of Actavis, another Icelandic generics... View Details
Keywords: Pharmaceutical Companies; Generic Drugs; Entrepreneurship; Globalization; Risk and Uncertainty; Pharmaceutical Industry; Iceland
Isenberg, Daniel, and William Kerr. "Alvogen." Harvard Business School Case 816-064, February 2016. (Revised February 2017.)
- November 2007
- Supplement
Teva Pharmaceutical Industries, Ltd.
By: Tarun Khanna and Krishna G. Palepu
How do companies develop a strategy that is both low-cost and differentiated without becoming squeezed in the middle? Describes how Teva, Israel's largest and first multinational, achieved its globally dominant position in generic pharmaceuticals, an industry that has... View Details
Keywords: Multinational Firms and Management; Emerging Markets; Rank and Position; Competitive Strategy; Pharmaceutical Industry; Israel; India
Khanna, Tarun, and Krishna G. Palepu. "Teva Pharmaceutical Industries, Ltd." Harvard Business School Video Supplement 708-806, November 2007.
- Research Summary
Multinational Enterprises and Corporate Responsibility
By: Nien-he Hsieh
Multinational enterprises, especially those operating in developing economies, face wide-ranging demands to help persons whose basic needs are unmet. Pharmaceutical companies, for example, are asked to provide access to life-saving therapies to patients in countries... View Details
- February 2002 (Revised March 2002)
- Case
India's Intellectual Property Rights Regime and the Pharmaceutical Industry
In 1970, the Indian government significantly revised its patent law, Patents and Design Act of 1911. The 1911 act was enacted when India was a colony of Great Britain, and it was controversial because it led to the total dominance of India's pharmaceutical market by... View Details
Huang, Yasheng, and Hal Hogan. "India's Intellectual Property Rights Regime and the Pharmaceutical Industry." Harvard Business School Case 702-039, February 2002. (Revised March 2002.)
- January 2021 (Revised June 2021)
- Case
Hester Pharmaceuticals (A): A Pricing Dilemma
By: Dante Roscini and John Masko
In August 2019, the leadership of Hester Pharmaceuticals (Hester) had a problem. Italy promised to be a key market for their new breakthrough oncology drug Akrozumab, but for almost two years, its single-payer healthcare system had been unable to agree with Hester on a... View Details
Keywords: Macroeconomics; Trade; Price; Global Range; Global Strategy; Globalized Markets and Industries; Health Care and Treatment; Patents; Monopoly; Negotiation; Business and Government Relations; Risk and Uncertainty; Human Needs; Business Strategy; Commercialization; Pharmaceutical Industry; Italy
Roscini, Dante, and John Masko. "Hester Pharmaceuticals (A): A Pricing Dilemma." Harvard Business School Case 721-001, January 2021. (Revised June 2021.)
- September 2021 (Revised October 2022)
- Supplement
Hester Pharmaceuticals (B): Securing Supply
By: Dante Roscini and John Masko
Supplements the (A) case. In late 2020, demand for Hester Pharmaceutical’s (Hester’s) breakthrough oncology drug Akrozumab was outstripping the company’s most optimistic projections. In order to increase manufacturing capacity and meet the demand, Hester was... View Details
Keywords: COVID-19 Pandemic; Cost vs Benefits; Trade; Supply Chain; Global Strategy; Buildings and Facilities; Operations; Health Care and Treatment; Demand and Consumers; Global Range; Globalized Markets and Industries; Pharmaceutical Industry; Italy; China; United States; Germany
Roscini, Dante, and John Masko. "Hester Pharmaceuticals (B): Securing Supply." Harvard Business School Supplement 722-009, September 2021. (Revised October 2022.)
- 30 Mar 2012
- HBS Seminar
Matthew W. Emmens, Executive Chairman,Vertex Pharmaceuticals
- 1999
- Chapter
Multinational Cross-Investment between Switzerland and Britain 1914-1945
By: G. Jones
This chapter examines multinational cross-investment between Switzerland and Great Britain between 1914 and 1945. While Great Britain and Switzerland were both major home economies for multinationals,few companies from either country were interested in investing in the... View Details
- December 2020
- Article
Multinational Firms and the Politics of International Trade in Multidisciplinary Perspective
By: Grace A. Ballor and Aydin B. Yildirim
From the technical analyses of wide ranges of scholars to the public discourse backlashes against globalization, there is a huge volume of work historicizing, quantifying, and problematizing the complex role of multinational corporations (MNCs) in international trade.... View Details
Keywords: Multinational Corporations; International Trade; Big Business; Economic Governance; Global Value Chains; Trade Policy; Corporate Regulation; Multinational Firms and Management; Trade; Policy; Governance; Globalization
Ballor, Grace A., and Aydin B. Yildirim. "Multinational Firms and the Politics of International Trade in Multidisciplinary Perspective." Special Issue on Multinational Corporations and the Politics of International Trade. Business and Politics 22, no. 4 (December 2020): 573–586.